Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10869-10878

  Kawakubo, Tomoyo ^a   Okamoto, Kuniaki ^d   Iwata, Jun Ichi ^a   Shin, Masashi ^a   Okamoto, Yoshiko ^c   Yasukochi, Atsushi ^a   Nakayama, Keiichi I ^b   Kadowaki, Tomoko ^a   Tsukuba, Takayuki ^a   Yamamoto, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE C; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CARCINOMA; CATHEPSIN E; CELL MEMBRANE; HUMANS; IMMUNE SYSTEM; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 36349007731     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2048     Document Type: Article

References (50)

1. Nomura T, Katsunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer. J Med Invest 2005;52:1-9.
2. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
3. Yamamoto K. Cathepsin E and cathepsin D. In Turk V, editor. Proteases: new perspectives. Basel: Birkhäser Verlag; 1999. p. 59-71.
4. Nishioku T, Hashimoto K, Yamashita K, et al. Involvement of cathepsin E in exogenous antigen processing in primary cultured murine microglia. J Biol Chem 2002;277:4816-22.
5. Sakai H, Saku T, Kato Y, et al. Quantitation and immunohistochemical localization of cathepsin E and D in rat tissues and blood cells. Biochim Biophys Acta 1989;991:367-75.
6. Bennett K, Levine T, Ellis JS, et al. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur J Immunol 1992;22:1519-24.
7. Chain BM, Free P, Medd P, et al. The expression and function of cathepsin E in dendritic cells. J Immunol 2005;174:1791-800.
8. Tsukuba T, Okamoto K, Okamoto Y, et al. Association of cathepsin E deficiency with development of atopic dermatitis. J Biochem 2003;134:893-902.
9. Tsukuba T, Yamamoto S, Yanagawa M, et al. Cathepsin E-deficient mice show increased susceptibility to bacterial infection associated with the decreased expression of multiple cell surface Toll-like receptors. J Biochem 2006;140:57-66.
10. Yanagawa M, Tsukuba T, Nishioku T, et al. Cathepsin E deficiency induces a novel form of lysosomal storage disorder showing the accumulation of lysosomal membrane sialoglycoproteins and the elevation of lysosomal pH in macrophages. J Biol Chem 2007;282:1851-62.
11. Ullmann R, Morbini P, Halbwedl I, et al. Protein expression profiles in adenocarcinomas and squamous cell carcinomas of the lung generated using tissue microarrays. J Pathol 2004;203:798-807.
12. Busquets L, Guillen H, DeFord ME, et al. Cathepsin E is a specific marker of dysplasia in APC mouse intestine. Tumor Biol 2006;27:36-42.
13. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11:4044-55.
14. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11:4415-29.
15. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
16. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
17. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
18. Cha SS, Kim YH, Choi BJ, et al. 2.8 Å resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999;11:253-61.
19. Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Moll Cell 1999;4:563-71.
20. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998;28:973-82.
21. Yasuda Y, Kohmura K, Kadowaki T, et al. A new selective substrate for cathepsin E based on the cleavage site sequence of α2-macroglobulin. Biol Chem 2005;386:299-305.
22. Liu J, Tsukuba T, Okamoto K, et al. Mutational analysis of residues in two consensus motifs in the active sites of cathepsin E. J Biochem 2002;132:493-9.
23. Yamamoto K, Katsuda N, Kato K. Affinity purification and properties of cathepsin E-like acid proteinase from rat spleen. Eur J Biochem 1978;92:499-508.
24. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-72.
25. Seol D, Billiar TR. Cysteine 230 modulates tumor necrosis factor - related apoptosis-inducing ligand activity. Cancer Res 2000;60:3152-4.
26. Bodmer J, Meier P, Tschopp J, et al. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000;275:20632-7.
27. Hymowitz SG, O'Connell MP, Ultsch MH, et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000;39:633-40.
28. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-63.
29. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998;64:419-26.
30. Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-53.
31. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999;163:1906-13.
32. Fanger NA, Maliszewski CR, Schooley K, et al. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-64.
33. Sastradipura DF, Nakanishi H, Tsukuba T, et al. Identification of cellular compartments involved in processing of cathepsin E in primary cultures of rat microglia. J Neurochem 1998;70:2045-56.
34. Yanagawa H, Takeuchi E, Suzuki Y, et al. Presence and potent immunosuppressive role of interleukin-10 in malignant pleural effusion due to lung cancer. Cancer Lett 1999;136:27-32.
35. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988;141:2407-12.
36. 2a antibodies to tumors destroy human cancer cells. Science 1983;221:865-7.
37. te Velde AA, Figdor CC. Monocyte mediated cytotoxic activity against melanoma. Melanoma Res 1992;1:303-9.
38. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997;385:729-33.
39. Kayagaki N, Yamaguchi N, Nakayama M, et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451-60.
40. Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol 1998;28:1492-8.
41. Kashii Y, Giorda R, Herberman RB, et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999;163:5358-66.
42. Varney ML, Olsen KJ, Mosley RL, et al. Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: a paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo 2002;16:471-7.
43. Takeda K, Smyth MJ, Cretney E, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cellular Immunol 2001;214:194-200.
44. + macrophages in antitumor cytotoxicity. Lab Invest 1992;67:166-74.
45. Naama HA, Mack VE, Smyth GP, et al. Macrophage effector mechanisms in melanoma in an experimental study. Arch Surg 2001;136:804-9.
46. Yanagawa M, Tsukuba T, Okamoto K, et al. Up-regulation, enhanced maturation, and secretion of cathepsin E in mouse macrophages treated with interferon-γ or lipopolysaccharide. J Oral Biosci 2006;48:218-25.
47. Hussein MR. Tumour-associated macrophages and melanoma tumorigenesis: integrating the complexity. Int J Exp Pathol 2006;87:163-76.
48. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
49. Lin EY, Nguyen AV, Russel RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-39.
50. Morin P, Sagné C, Gasnier B. Functional characterization of wild-type and mutant human sialin. EMBO J 2004;23:4560-70.